Factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study

S. A. V. Nieuwenburg; M. C. Mommersteeg; E. L. Eikenboom; B. Yu; W. J. den Hollander; I. Lisanne Holster; Caroline M. den Hoed; L. G Capelle; Thjon J. Tang; Marie-Paule Anten; I. Prytz-Berset; E. M. Witteman; F. ter Borg; Jordy P. W. Burger; Marco J. Bruno; G. M. Fuhler; Maikel P. Peppelenbosch; Michael Doukas; Ernst J. Kuipers; Manon C.W. Spaander

doi:10.1055/a-1314-6626

Endoscopy International Open, Table of Contents

CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(03): E297-E305
DOI: 10.1055/a-1314-6626

Original article

Factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study

S. A. V. Nieuwenburg

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

M. C. Mommersteeg‡

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

E. L. Eikenboom‡

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

B. Yu

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

W. J. den Hollander

²Leiden University Medical Centre, Leiden, The Netherlands

,

I. Lisanne Holster

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

Caroline M. den Hoed

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

L. G Capelle

³Meander Medical Centre, Amersfoort, the Netherlands

,

Thjon J. Tang

⁴IJsselland Hospital, Capelle aan den IJssel, The Netherlands

,

Marie-Paule Anten

⁵Sint Franciscus Hospital, Rotterdam, The Netherlands

,

I. Prytz-Berset

⁶More and Romsdal Trust Ålesund, Ålesund, Norway

,

E. M. Witteman

⁷Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

,

F. ter Borg

⁸Deventer Hospital, Deventer, The Netherlands

,

Jordy P. W. Burger

⁹Department of Gastroenterology and Hepatology, Rijnstate, Arnhem, The Netherlands

,

Marco J. Bruno

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

G. M. Fuhler

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

Maikel P. Peppelenbosch

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

Michael Doukas

¹⁰Department of Pathology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

Ernst J. Kuipers

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

,

Manon C.W. Spaander

¹Departments of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands

› Author Affiliations

Abstract

Background and study aims Gastric cancer (GC) is usually preceded by premalignant gastric lesions (GPLs) such as gastric intestinal metaplasia (GIM). Information on risk factors associated with neoplastic progression of GIM are scarce. This study aimed to identify predictors for progression of GIM in areas with low GC incidence.

Patients and methods The Progression and Regression of Precancerous Gastric Lesions (PROREGAL) study includes patients with GPL. Patients underwent at least two upper endoscopies with random biopsy sampling. Progression of GIM means an increase in severity according to OLGIM (operative link on gastric intestinal metaplasia) during follow-up (FU). Family history and lifestyle factors were determined through questionnaires. Serum Helicobacter pylori infection, pepsinogens (PG), gastrin-17 and GC-associated single nucleotide polymorphisms (SNPs) were determined. Cox regression was performed for risk analysis and a chi-squared test for analysis of single nucleotide polymorphisms.

Results Three hundred and eight patients (median age at inclusion 61 years, interquartile range (IQR: 17; male 48.4 %; median FU 48 months, IQR: 24) were included. During FU, 116 patients (37.7 %) showed progression of IM and six patients (1.9 %) developed high-grade dysplasia or GC. The minor allele (C) on TLR4 (rs11536889) was inversely associated with progression of GIM (OR 0.6; 95 %CI 0.4–1.0). Family history (HR 1.5; 95 %CI 0.9–2.4) and smoking (HR 1.6; 95 %CI 0.9–2.7) showed trends towards progression of GIM. Alcohol use, body mass index, history of H. pylori infection, and serological markers were not associated with progression.

Conclusions Family history and smoking appear to be related to an increased risk of GIM progression in low GC incidence countries. TLR4 (rs11536889) showed a significant inverse association, suggesting that genetic information may play a role in GIM progression.

Full Text

References

References
1 IARC Working Group. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241
2 Plummer M, Franceschi S, Vignat J. et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015; 136: 487-490
3 Fock KM, Talley N, Moayyedi P. et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-365
4 Dinis-Ribeiro M, Areia M, de Vries AC. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94
5 Trieu JA, Bilal M, Saraireh H. et al. Update on the diagnosis and management of gastric intestinal metaplasia in the USA. Dig Dis Sci 2019; 64: 1079-1088
6 Banks M, Graham D, Jansen M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019; 68: 1545-1575
7 Evans JA, Chandrasekhara V. ASGE Standard of Practice Committee. et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc 2015; 82: 1-8
8 Gupta S, Li D, El Serag HB. et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158: 693-702
9 Pimentel-Nunes P, Libanio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-388
10 Oliveira C, Pinheiro H, Figueiredo J. et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015; 16: e60-70
11 Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2010; 102: 237-242
12 Safaee A, Moghimi-Dehkordi B, Fatemi SR. et al. Family history of cancer and risk of gastric cancer in Iran. Asian Pac J Cancer Prev 2011; 12: 3117-3120
13 Castano-Rodriguez N, Kaakoush NO, Goh KL. et al. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS One 2013; 8: e60327
14 Castano-Rodriguez N, Kaakoush NO, Pardo AL. et al. Genetic polymorphisms in the Toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer. Hum Immunol 2014; 75: 808-815
15 Castano-Rodriguez N, Kaakoush NO, Goh KL. et al. Autophagy in Helicobacter pylori infection and related gastric cancer. Helicobacter 2015; 20: 353-369
16 Leung WK, Lin SR, Ching JY. et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-1249
17 Rota M, Pelucchi C, Bertuccio P. et al. Alcohol consumption and gastric cancer risk-A pooled analysis within the StoP project consortium. Int J Cancer 2017; 141: 1950-1962
18 Huang YK, Yu JC, Kang WM. et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and Meta-Analysis. PLoS One 2015; 10: e0142080
19 Hunt RH, Camilleri M, Crowe SE. et al. The stomach in health and disease. Gut 2015; 64: 1650-1668
20 den Hollander WJ, Holster IL, den Hoed CM. et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut 2018; 68: 585-593
21 Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2018; 21: 579-587
22 Tang FB, Li ZX, Wang YM. et al. Toll-like receptor 1 and 10 polymorphisms, Helicobacter pylori susceptibility and risk of gastric lesions in a high-risk Chinese population. Infect Genet Evol 2015; 31: 263-269
23 Zhang K, Zhou B, Wang Y. et al. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer 2013; 49: 946-954
24 Ryan BM, Zanetti KA, Robles AI. et al. Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer. Int J Cancer 2014; 134: 1399-1407
25 Burada F, Ciurea ME, Nicoli R. et al. ATG16L1 T300A polymorphism is correlated with gastric cancer susceptibility. Pathol Oncol Res 2016; 22: 317-322
26 Ikram MA, Brusselle GGO, Murad SD. et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol 2017; 32: 807-850
27 Peduzzi P, Concato J, Feinstein AR. et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48: 1503-1510
28 Zagari RM, Rabitti S, Greenwood DC. et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017; 46: 657-667
29 Wong BC, Lam SK, Wong WM. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. Jama 2004; 291: 187-194
30 Ma JL, Zhang L, Brown LM. et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104: 488-492
31 Lin XJ, Wang CP, Liu XD. et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol 2014; 44: 783-791
32 Kneller RW, You WC, Chang YS. et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992; 84: 1261-1266
33 Okada E, Ukawa S, Nakamura K. et al. Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project. J Epidemiol 2017; 27: S29-S35
34 Tramacere I, Negri E, Pelucchi C. et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2012; 23: 28-36
35 Kim K, Chang Y, Ahn J. et al. Smoking and urinary cotinine levels are predictors of increased risk for gastric intestinal metaplasia. Cancer Res 2019; 79: 676-684
36 Nieminen AA, Kontto J, Puolakkainen P. et al. Long-term gastric cancer risk in male smokers with atrophic corpus gastritis. Scand J Gastroenterol 2019; 54: 145-151
37 Altayar O, Davitkov P, Shah SC. et al. AGA technical review on gastric intestinal metaplasia-epidemiology and risk factors. Gastroenterology 2020; 158: 732-744 e716
38 Leja M, Kupcinskas L, Funka K. et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 2011; 56: 145-150
39 Lahner E, Esposito G, Pilozzi E. et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol 2015; 50: 856-865
40 Reddy KM, Chang JI, Shi JM. et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. Clin Gastroenterol Hepatol 2016; 14: 1420-1425
41 Cooney R, Baker J, Brain O. et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-97
42 Mommersteeg MC, Yu J, Peppelenbosch MP. et al. Genetic host factors in Helicobacter pylori-induced carcinogenesis: Emerging new paradigms. Biochim Biophys Acta Rev Cancer 2018; 1869: 42-52
43 Mayerle J, den Hoed CM, Schurmann C. et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 2013; 309: 1912-1920
44 Dargiene G, Streleckiene G, Skieceviciene J. et al. TLR1 and PRKAA1 gene polymorphisms in the development of atrophic gastritis and gastric cancer. J Gastrointestin Liver Dis 2018; 27: 363-369
45 Loh M, Koh KX, Yeo BH. et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 2009; 45: 2562-2568
46 Lu B, Chen MT, Fan YH. et al. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol 2005; 11: 6518-6520
47 Sung JJ, Lin SR, Ching JY. et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 7-14

Supplementary Material

Supplementary material